Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

Journal:
Nature Medicine
Published:
Affiliations:
29
Authors:
24
Institutions Authors Share
Medica Scientia Innovation Research (MedSIR), Spain
5.694444
0.24
Hospital Universitario Ramón y Cajal, Spain
1.333333
0.06
Arnau de Vilanova University Hospital (HUAV), ICS, Spain
1.333333
0.06
University Medical Centre Mannheim (UMM) at Medical Faculty Mannheim, Uni Heidelberg, Germany
1.000000
0.04
Quirónsalud Hospital in Valencia, Spain
1.000000
0.04
University Hospital of Sant Joan d'Alacant, Spain
1.000000
0.04
MD Anderson Cancer Center Madrid, Spain
1.000000
0.04
Hospital de San Juan Despí Moisès Broggi, Spain
1.000000
0.04
Virgen del Rocío University Hospital, Spain
1.000000
0.04
University of Las Palmas de Gran Canaria (ULPGC), Spain
1.000000
0.04
University Hospital of La Ribera, Spain
1.000000
0.04
IRCCS Istituto Nazionale Tumori IRCCS-Fondazione G. Pascale, Italy
1.000000
0.04
IOB Institute of Oncology, Spain
0.944444
0.04
Hospital Beata María Ana, Spain
0.944444
0.04
Instituto Oncologico Dr. Rosell, Spain
0.500000
0.02
Dexeus University Hospital, Spain
0.500000
0.02
IRCCS European Institute of Oncology (IEO), Italy
0.500000
0.02
University of Milan (UNIMI), Italy
0.500000
0.02
International Breast Cancer Center (IBCC), Spain
0.361111
0.02
Pangaea Oncology SA, Spain
0.361111
0.02
Quirónsalud, Spain
0.361111
0.02
San Cecilio University Hospital, Spain
0.333333
0.01
University of Granada (UGR), Spain
0.333333
0.01
Instituto de Investigación Biosanitaria de Granada (ibs.Granada), Spain
0.333333
0.01
CEU Cardinal Herrera University, Spain
0.333333
0.01
European University of Madrid (UEM), Spain
0.111111
0.00
Hospital Universitario Torrejón, Spain
0.111111
0.00
Ribera Salud Grupo, Spain
0.111111
0.00